{ "updated": "2026-11-02", "about": "从图谱融资记录拆出的投资方。sum_usd 是这些轮的整轮金额合计，不是该机构自己出的钱。", "investors": [ { "name": "NVIDIA", "type": "产业资本", "companies": [ "Vilya", "EvolutionaryScale", "Terray Therapeutics", "Achira", "Charm Therapeutics", "Proxima（原 Vant AI）", "Lila Sciences", "Basecamp Research" ], "articles": [], "rounds": [ { "company": "Vilya", "date": "2024-06", "round": "A 轮扩展", "amount": "总额 $7100 万", "role": "跟投", "post": "", "src": "https://cen.acs.org/pharmaceuticals/drug-discovery/Vilya-designs-new-macrocyclic-peptides/102/i35" }, { "company": "EvolutionaryScale", "date": "2024-06", "round": "种子轮", "amount": "$142M", "role": "跟投", "post": "", "src": "https://pharmaphorum.com/news/evolutionaryscale-emerges-142m-ai-drug-discovery" }, { "company": "Terray Therapeutics", "date": "2024-10", "round": "B 轮", "amount": "$1.2 亿", "role": "领投", "post": "", "src": "https://sogotradedev.websol.barchart.com/?module=topNews&storyID=29084499&selected=news&symbol=" }, { "company": "Achira", "date": "2025-02", "round": "种子/A 轮（媒体称法不一）", "amount": "$3300 万", "role": "跟投", "post": "", "src": "https://www.powergame.gr/start-ups-digital/812090/achira-33-ekat-dolaria-apo-tin-nvidia-sti-startup-me-to-elliniko-dna/" }, { "company": "Charm Therapeutics", "date": "2025-09", "round": "B 轮", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://multiples.vc/private-comps/charm-therapeutics" }, { "company": "Proxima（原 Vant AI）", "date": "2026-01", "round": "种子轮（改名 Proxima）", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://htworld.co.uk/news/ai/proxima-raises-us80-million-for-ai-drug-discovery-platform-lead26/" }, { "company": "Lila Sciences", "date": "2026-07-31", "round": "B 轮（B-1 $14.6 亿 + B-2 $5.4 亿，Forge 口径）", "amount": "约 $20 亿", "role": "领投", "post": "$85 亿", "src": "https://forgeglobal.com/lila-sciences_ipo/#companyDetails" }, { "company": "Basecamp Research", "date": "2026-09", "round": "C 轮", "amount": "$140M", "role": "跟投", "post": "投后 $8 亿（媒体报道）", "src": "https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics" } ], "sum_usd": 2666000000 }, { "name": "a16z", "type": "VC / 基金", "companies": [ "Genesis Molecular AI", "Formation Bio", "Boltz", "BigHat Biosciences" ], "articles": [], "rounds": [ { "company": "Genesis Molecular AI", "date": "2023", "round": "B 轮", "amount": "约 $2.04 亿", "role": "领投", "post": "", "src": "https://leadiq.com/c/genesis-molecular-ai/5d118ae41e00003600d858f0" }, { "company": "Formation Bio", "date": "2024-06", "round": "D 轮", "amount": "$3.72 亿", "role": "领投", "post": "", "src": "https://builtincharlotte.com/company/formation-bio/faq/stability-growth" }, { "company": "Boltz", "date": "2026-01", "round": "种子轮", "amount": "$28M", "role": "领投", "post": "", "src": "https://www.communityjameel.org/news/mit-jameel-clinic-spinout-boltz-launches-new-platform-and-agents-announces-usd-28m-seed-round" }, { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "跟投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" } ], "sum_usd": 679000000 }, { "name": "Dimension", "type": "VC / 基金", "companies": [ "Achira", "Automata", "Tamarind Bio", "Chai Discovery" ], "articles": [], "rounds": [ { "company": "Achira", "date": "2025-02", "round": "种子/A 轮（媒体称法不一）", "amount": "$3300 万", "role": "领投", "post": "", "src": "https://www.powergame.gr/start-ups-digital/812090/achira-33-ekat-dolaria-apo-tin-nvidia-sti-startup-me-to-elliniko-dna/" }, { "company": "Automata", "date": "2026-01", "round": "C 轮", "amount": "$45M", "role": "领投", "post": "", "src": "https://www.rdworldonline.com/automata-raises-45m-to-scale-lab-automation-platform-adds-danaher-as-strategic-investor/" }, { "company": "Tamarind Bio", "date": "2026-02", "round": "A 轮", "amount": "$13.6M（累计口径；部分媒体称本轮 $12M）", "role": "领投", "post": "", "src": "https://www.genengnews.com/topics/artificial-intelligence/tamarind-bio-secures-13-6m-series-a-to-make-ai-more-accessible-for-biology/" }, { "company": "Chai Discovery", "date": "2026-07", "round": "C 轮", "amount": "$400M", "role": "跟投", "post": "投后 $38 亿", "src": "https://www.zhiding.cn/energy/2026/0715/3193267.shtml" } ], "sum_usd": 491600000 }, { "name": "Lux Capital", "type": "VC / 基金", "companies": [ "Strateos", "EvolutionaryScale", "Inductive Bio", "Paradigm Health" ], "articles": [], "rounds": [ { "company": "Strateos", "date": "2021-06", "round": "B 轮", "amount": "$56.1M", "role": "领投", "post": "", "src": "https://healthcarediscovery.ai/companies/transcriptic/" }, { "company": "EvolutionaryScale", "date": "2024-06", "round": "种子轮", "amount": "$142M", "role": "领投", "post": "", "src": "https://pharmaphorum.com/news/evolutionaryscale-emerges-142m-ai-drug-discovery" }, { "company": "Inductive Bio", "date": "2025-05", "round": "A 轮", "amount": "$2500 万", "role": "跟投", "post": "", "src": "https://www.finsmes.com/2025/05/inductive-bio-raises-25m-in-series-a-funding.html" }, { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "跟投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" } ], "sum_usd": 301100000 }, { "name": "GV", "type": "VC / 基金", "companies": [ "Arda Therapeutics", "Paradigm Health", "Isomorphic Labs" ], "articles": [], "rounds": [ { "company": "Arda Therapeutics", "date": "2024-10", "round": "A 轮", "amount": "$4300 万", "role": "跟投", "post": "", "src": "https://www.ardatx.com/news/arda-therapeutics-secures-43m-series-a-financing-to-advance-targeted-cell-depletion-therapies" }, { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "跟投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" }, { "company": "Isomorphic Labs", "date": "2026-05", "round": "B 轮", "amount": "$21 亿", "role": "跟投", "post": "", "src": "https://www.linkedin.com/posts/leonardrinser_breaking-isomorphic-labs-raises-21-billion-activity-7462389174961238016-o1SC" } ], "sum_usd": 2221000000 }, { "name": "ARCH Venture Partners", "type": "VC / 基金", "companies": [ "Xaira Therapeutics", "Vilya", "Paradigm Health" ], "articles": [], "rounds": [ { "company": "Xaira Therapeutics", "date": "2024-04", "round": "启动融资", "amount": ">$10 亿（承诺资本）", "role": "领投", "post": "", "src": "https://www.ddw-online.com/ai-drug-discovery-company-xaira-launches-with-1b-investment-29500-202404/" }, { "company": "Vilya", "date": "2024-06", "round": "A 轮扩展", "amount": "总额 $7100 万", "role": "领投", "post": "", "src": "https://cen.acs.org/pharmaceuticals/drug-discovery/Vilya-designs-new-macrocyclic-peptides/102/i35" }, { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "领投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" } ], "sum_usd": 1149000000 }, { "name": "Sanofi", "type": "产业资本", "companies": [ "Owkin", "Formation Bio", "QuantHealth" ], "articles": [], "rounds": [ { "company": "Owkin", "date": "2021-11", "round": "Sanofi 股权投资", "amount": "$1.8 亿", "role": "领投", "post": "估值超 $10 亿", "src": "https://www.thepharmaletter.com/ones-to-watch/owkin" }, { "company": "Formation Bio", "date": "2024-06", "round": "D 轮", "amount": "$3.72 亿", "role": "跟投", "post": "", "src": "https://builtincharlotte.com/company/formation-bio/faq/stability-growth" }, { "company": "QuantHealth", "date": "2026-08", "round": "B 轮", "amount": "$45M", "role": "跟投", "post": "", "src": "https://hitconsultant.net/2026/08/04/beyond-real-world-trial-iteration-quanthealth-secures-45m-for-ai-clinical-simulation/" } ], "sum_usd": 597000000 }, { "name": "Catalio Capital", "type": "VC / 基金", "companies": [ "BigHat Biosciences", "Enveda Biosciences", "Basecamp Research" ], "articles": [], "rounds": [ { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "跟投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" }, { "company": "Enveda Biosciences", "date": "2026-09", "round": "E 轮", "amount": "$3.11 亿", "role": "领投", "post": "估值约 $20 亿（TechCrunch 转述）", "src": "https://finance.yahoo.com/healthcare/articles/enveda-raises-311-million-doubles-140548364.html" }, { "company": "Basecamp Research", "date": "2026-09", "round": "C 轮", "amount": "$140M", "role": "跟投", "post": "投后 $8 亿（媒体报道）", "src": "https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics" } ], "sum_usd": 526000000 }, { "name": "S32", "type": "VC / 基金", "companies": [ "Inductive Bio", "Faro Health", "Basecamp Research" ], "articles": [], "rounds": [ { "company": "Inductive Bio", "date": "2025-05", "round": "A 轮", "amount": "$2500 万", "role": "跟投", "post": "", "src": "https://www.finsmes.com/2025/05/inductive-bio-raises-25m-in-series-a-funding.html" }, { "company": "Faro Health", "date": "2026-08", "round": "B 轮", "amount": "$37.3M", "role": "领投", "post": "", "src": "https://catalyze.gunder.com/en/news-insights/client-news/faro-ai-announces-dollar373-million-series-b" }, { "company": "Basecamp Research", "date": "2026-09", "round": "C 轮", "amount": "$140M", "role": "领投", "post": "投后 $8 亿（媒体报道）", "src": "https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics" } ], "sum_usd": 202300000 }, { "name": "Eli Lilly", "type": "产业资本", "companies": [ "Strateos", "Arda Therapeutics", "Absci" ], "articles": [], "rounds": [ { "company": "Strateos", "date": "2021-06", "round": "B 轮", "amount": "$56.1M", "role": "跟投", "post": "", "src": "https://healthcarediscovery.ai/companies/transcriptic/" }, { "company": "Arda Therapeutics", "date": "2024-10", "round": "A 轮", "amount": "$4300 万", "role": "跟投", "post": "", "src": "https://www.ardatx.com/news/arda-therapeutics-secures-43m-series-a-financing-to-advance-targeted-cell-depletion-therapies" }, { "company": "Absci", "date": "2026-06", "round": "承销公开发行", "amount": "$1 亿（含 Eli Lilly $4000 万战略投资）", "role": "领投", "post": "", "src": "https://investors.absci.com/news-and-events/news-releases" } ], "sum_usd": 199100000 }, { "name": "General Catalyst", "type": "VC / 基金", "companies": [ "Manas AI", "Paradigm Health", "Faro Health" ], "articles": [ { "title": "The Future of Life Sciences Investment", "date": "2025-06-25", "url": "https://www.generalcatalyst.com/stories/the-future-of-life-sciences-investment", "kind": "赛道论点" } ], "rounds": [ { "company": "Manas AI", "date": "2025", "round": "两轮种子", "amount": "超过 $5000 万", "role": "领投", "post": "", "src": "https://thenextweb.com/news/reid-hoffman-leaves-microsoft-board-manas" }, { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "跟投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" }, { "company": "Faro Health", "date": "2026-08", "round": "B 轮", "amount": "$37.3M", "role": "跟投", "post": "", "src": "https://catalyze.gunder.com/en/news-insights/client-news/faro-ai-announces-dollar373-million-series-b" } ], "sum_usd": 165300000 }, { "name": "DCVC", "type": "VC / 基金", "companies": [ "Strateos", "Noetik", "Proxima（原 Vant AI）" ], "articles": [ { "title": "Relation defines the TechBio sector with AI models transforming drug discovery", "date": "2026-07-30", "url": "https://www.dcvc.com/news-insights/relation-defines-the-techbio-sector-with-ai-models-transforming-drug-discovery", "kind": "投资备忘" }, { "title": "Deep Tech Opportunity: TechBio companies are using data to rethink how we develop new medical treatments", "date": "2026-03-02", "url": "https://www.dcvc.com/news-insights/deep-tech-opportunity-techbio-companies-are-using-data-to-rethink-how-we-develop-new-medical-treatments/", "kind": "赛道论点" }, { "title": "Noetik's partnership with GSK puts dollar signs on the AI licensing business model in TechBio", "date": "2026-01-08", "url": "https://www.dcvc.com/news-insights/noetiks-partnership-with-gsk-puts-dollar-signs-on-the-ai-licensing-business-model-in-techbio", "kind": "投资备忘" } ], "rounds": [ { "company": "Strateos", "date": "2021-06", "round": "B 轮", "amount": "$56.1M", "role": "领投", "post": "", "src": "https://healthcarediscovery.ai/companies/transcriptic/" }, { "company": "Noetik", "date": "2023", "round": "种子轮", "amount": "$14M", "role": "领投", "post": "", "src": "https://aiproplaybook.com/companies/noetik" }, { "company": "Proxima（原 Vant AI）", "date": "2026-01", "round": "种子轮（改名 Proxima）", "amount": "$8000 万", "role": "领投", "post": "", "src": "https://htworld.co.uk/news/ai/proxima-raises-us80-million-for-ai-drug-discovery-platform-lead26/" } ], "sum_usd": 150100000 }, { "name": "Khosla", "type": "VC / 基金", "companies": [ "Nabla Bio", "Noetik", "Charm Therapeutics" ], "articles": [ { "title": "Vinod Khosla：AI 造成药物与生物学假设的「超充裕」，但测试仍停留在 18 世纪（X 帖）", "date": "2026-08-12", "url": "https://x.com/vkhosla/status/2087558432605769838", "kind": "赛道论点" } ], "rounds": [ { "company": "Nabla Bio", "date": "2024-05", "round": "A 轮", "amount": "约 $2586 万（Forge 口径）", "role": "跟投", "post": "", "src": "https://forgeglobal.com/nabla-bio_ipo/" }, { "company": "Noetik", "date": "2024-08", "round": "A 轮", "amount": "$40M", "role": "跟投", "post": "", "src": "https://www.businesswire.com/news/home/20240829428359/en/Noetik-Secures-$40-Million-Series-A-Financing-to-Advance-Precision-Cancer-Therapies" }, { "company": "Charm Therapeutics", "date": "2025-09", "round": "B 轮", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://multiples.vc/private-comps/charm-therapeutics" } ], "sum_usd": 145860000 }, { "name": "Amplify Partners", "type": "VC / 基金", "companies": [ "Achira", "Tahoe Therapeutics", "Boltz" ], "articles": [ { "title": "Amplify Bio Manifesto", "date": "2025-05-30", "url": "https://www.amplifypartners.com/blog-posts/amplify-bio-manifesto", "kind": "赛道论点" } ], "rounds": [ { "company": "Achira", "date": "2025-02", "round": "种子/A 轮（媒体称法不一）", "amount": "$3300 万", "role": "跟投", "post": "", "src": "https://www.powergame.gr/start-ups-digital/812090/achira-33-ekat-dolaria-apo-tin-nvidia-sti-startup-me-to-elliniko-dna/" }, { "company": "Tahoe Therapeutics", "date": "2025-08", "round": "A 轮", "amount": "$30M", "role": "领投", "post": "", "src": "https://www.biopharmatrend.com/news/tahoe-therapeutics-raises-30-million-to-expand-single-cell-data-production-for-ai-models-1337/" }, { "company": "Boltz", "date": "2026-01", "round": "种子轮", "amount": "$28M", "role": "领投", "post": "", "src": "https://www.communityjameel.org/news/mit-jameel-clinic-spinout-boltz-launches-new-platform-and-agents-announces-usd-28m-seed-round" } ], "sum_usd": 91000000 }, { "name": "Cathay Innovation", "type": "VC / 基金", "companies": [ "Inato", "Aqemia", "Bioptimus" ], "articles": [], "rounds": [ { "company": "Inato", "date": "2023-03", "round": "A2 轮", "amount": "$20M", "role": "领投", "post": "", "src": "https://dealroom.co/companies/inato/" }, { "company": "Aqemia", "date": "2024", "round": "融资", "amount": "7000 万（币种未显示）", "role": "领投", "post": "", "src": "https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2026/03/Aqemia_FactSheet_Screen.pdf" }, { "company": "Bioptimus", "date": "2025-01", "round": "A 轮", "amount": "$41M", "role": "领投", "post": "", "src": "https://presse.bpifrance.fr/download?id=3183&n=" } ], "sum_usd": 61000000 }, { "name": "Index Ventures", "type": "VC / 基金", "companies": [ "Cradle", "Chai Discovery" ], "articles": [], "rounds": [ { "company": "Cradle", "date": "2024-11", "round": "B 轮", "amount": "$73M", "role": "跟投", "post": "", "src": "https://www.synbiobeta.com/read/ai-powered-protein-engineering-heightened-by-cradle-bios-73m-series-b" }, { "company": "Chai Discovery", "date": "2026-07", "round": "C 轮", "amount": "$400M", "role": "领投", "post": "投后 $38 亿", "src": "https://www.zhiding.cn/energy/2026/0715/3193267.shtml" } ], "sum_usd": 473000000 }, { "name": "DFJ Growth", "type": "VC / 基金", "companies": [ "Helix", "BigHat Biosciences" ], "articles": [], "rounds": [ { "company": "Helix", "date": "2018-03", "round": "B 轮", "amount": "$200M", "role": "领投", "post": "", "src": "https://profiles.crustdata.com/company/helix-631692" }, { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "领投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" } ], "sum_usd": 275000000 }, { "name": "F-Prime", "type": "VC / 基金", "companies": [ "Charm Therapeutics", "Paradigm Health" ], "articles": [], "rounds": [ { "company": "Charm Therapeutics", "date": "2025-09", "round": "B 轮", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://multiples.vc/private-comps/charm-therapeutics" }, { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "跟投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" } ], "sum_usd": 158000000 }, { "name": "Altimeter", "type": "VC / 基金", "companies": [ "Unlearn.AI", "Profluent" ], "articles": [ { "title": "AI Drug Discovery Is Becoming a Bottleneck Trade（华尔街见闻转述 Freda Duan 的帖子）", "date": "2026-10-04", "url": "https://awtmt.com/articles/3783019", "kind": "赛道论点" } ], "rounds": [ { "company": "Unlearn.AI", "date": "2024-02", "round": "C 轮", "amount": "$50M", "role": "领投", "post": "", "src": "https://physicianaitools.com/companies/unlearn/" }, { "company": "Profluent", "date": "2025-11", "round": "融资", "amount": "$106M", "role": "领投", "post": "", "src": "https://investor.wedbush.com/wedbush/article/bizwire-2025-11-19-profluent-raises-106m-to-scale-frontier-ai-models-for-programmable-biology" } ], "sum_usd": 156000000 }, { "name": "Sofinnova Partners", "type": "VC / 基金", "companies": [ "Bioptimus", "Latent Labs" ], "articles": [], "rounds": [ { "company": "Bioptimus", "date": "2024-02", "round": "种子轮", "amount": "$35M", "role": "领投", "post": "", "src": "https://presse.bpifrance.fr/download?id=3183&n=" }, { "company": "Latent Labs", "date": "2025-02", "round": "A 轮（含在出隐身 $50M 中）", "amount": "$40M", "role": "领投", "post": "", "src": "https://www.synbiobeta.com/read/inside-latent-labs-autonomous-drug-design-engine" } ], "sum_usd": 75000000 }, { "name": "Radical Ventures", "type": "VC / 基金", "companies": [ "Nabla Bio", "Latent Labs" ], "articles": [], "rounds": [ { "company": "Nabla Bio", "date": "2024-05", "round": "A 轮", "amount": "约 $2586 万（Forge 口径）", "role": "跟投", "post": "", "src": "https://forgeglobal.com/nabla-bio_ipo/" }, { "company": "Latent Labs", "date": "2025-02", "round": "A 轮（含在出隐身 $50M 中）", "amount": "$40M", "role": "领投", "post": "", "src": "https://www.synbiobeta.com/read/inside-latent-labs-autonomous-drug-design-engine" } ], "sum_usd": 65860000 }, { "name": "Obvious Ventures", "type": "VC / 基金", "companies": [ "Inato", "Inductive Bio" ], "articles": [ { "title": "Biological Awareness", "date": "2026-06-08", "url": "https://obvious.com/ideas/biological-awareness/", "kind": "赛道论点" } ], "rounds": [ { "company": "Inato", "date": "2023-03", "round": "A2 轮", "amount": "$20M", "role": "跟投", "post": "", "src": "https://dealroom.co/companies/inato/" }, { "company": "Inductive Bio", "date": "2025-05", "round": "A 轮", "amount": "$2500 万", "role": "领投", "post": "", "src": "https://www.finsmes.com/2025/05/inductive-bio-raises-25m-in-series-a-funding.html" } ], "sum_usd": 45000000 }, { "name": "Y Combinator", "type": "VC / 基金", "companies": [ "Nabla Bio", "Tamarind Bio" ], "articles": [], "rounds": [ { "company": "Nabla Bio", "date": "2024-05", "round": "A 轮", "amount": "约 $2586 万（Forge 口径）", "role": "跟投", "post": "", "src": "https://forgeglobal.com/nabla-bio_ipo/" }, { "company": "Tamarind Bio", "date": "2026-02", "round": "A 轮", "amount": "$13.6M（累计口径；部分媒体称本轮 $12M）", "role": "跟投", "post": "", "src": "https://www.genengnews.com/topics/artificial-intelligence/tamarind-bio-secures-13-6m-series-a-to-make-ai-more-accessible-for-biology/" } ], "sum_usd": 39460000 }, { "name": "Thrive Capital", "type": "VC / 基金", "companies": [ "Isomorphic Labs" ], "articles": [], "rounds": [ { "company": "Isomorphic Labs", "date": "2026-05", "round": "B 轮", "amount": "$21 亿", "role": "领投", "post": "", "src": "https://www.linkedin.com/posts/leonardrinser_breaking-isomorphic-labs-raises-21-billion-activity-7462389174961238016-o1SC" } ], "sum_usd": 2100000000 }, { "name": "Alphabet", "type": "产业资本", "companies": [ "Isomorphic Labs" ], "articles": [], "rounds": [ { "company": "Isomorphic Labs", "date": "2026-05", "round": "B 轮", "amount": "$21 亿", "role": "跟投", "post": "", "src": "https://www.linkedin.com/posts/leonardrinser_breaking-isomorphic-labs-raises-21-billion-activity-7462389174961238016-o1SC" } ], "sum_usd": 2100000000 }, { "name": "MGX", "type": "VC / 基金", "companies": [ "Isomorphic Labs" ], "articles": [], "rounds": [ { "company": "Isomorphic Labs", "date": "2026-05", "round": "B 轮", "amount": "$21 亿", "role": "跟投", "post": "", "src": "https://www.linkedin.com/posts/leonardrinser_breaking-isomorphic-labs-raises-21-billion-activity-7462389174961238016-o1SC" } ], "sum_usd": 2100000000 }, { "name": "Temasek", "type": "VC / 基金", "companies": [ "Isomorphic Labs" ], "articles": [], "rounds": [ { "company": "Isomorphic Labs", "date": "2026-05", "round": "B 轮", "amount": "$21 亿", "role": "跟投", "post": "", "src": "https://www.linkedin.com/posts/leonardrinser_breaking-isomorphic-labs-raises-21-billion-activity-7462389174961238016-o1SC" } ], "sum_usd": 2100000000 }, { "name": "CapitalG", "type": "VC / 基金", "companies": [ "Isomorphic Labs" ], "articles": [], "rounds": [ { "company": "Isomorphic Labs", "date": "2026-05", "round": "B 轮", "amount": "$21 亿", "role": "跟投", "post": "", "src": "https://www.linkedin.com/posts/leonardrinser_breaking-isomorphic-labs-raises-21-billion-activity-7462389174961238016-o1SC" } ], "sum_usd": 2100000000 }, { "name": "英国主权 AI 基金", "type": "VC / 基金", "companies": [ "Isomorphic Labs" ], "articles": [], "rounds": [ { "company": "Isomorphic Labs", "date": "2026-05", "round": "B 轮", "amount": "$21 亿", "role": "跟投", "post": "", "src": "https://www.linkedin.com/posts/leonardrinser_breaking-isomorphic-labs-raises-21-billion-activity-7462389174961238016-o1SC" } ], "sum_usd": 2100000000 }, { "name": "CalPERS", "type": "VC / 基金", "companies": [ "Lila Sciences" ], "articles": [], "rounds": [ { "company": "Lila Sciences", "date": "2026-07-31", "round": "B 轮（B-1 $14.6 亿 + B-2 $5.4 亿，Forge 口径）", "amount": "约 $20 亿", "role": "领投", "post": "$85 亿", "src": "https://forgeglobal.com/lila-sciences_ipo/#companyDetails" } ], "sum_usd": 2000000000 }, { "name": "Foresite", "type": "VC / 基金", "companies": [ "Xaira Therapeutics" ], "articles": [], "rounds": [ { "company": "Xaira Therapeutics", "date": "2024-04", "round": "启动融资", "amount": ">$10 亿（承诺资本）", "role": "领投", "post": "", "src": "https://www.ddw-online.com/ai-drug-discovery-company-xaira-launches-with-1b-investment-29500-202404/" } ], "sum_usd": 1000000000 }, { "name": "Carlyle", "type": "VC / 基金", "companies": [ "Saama" ], "articles": [], "rounds": [ { "company": "Saama", "date": "2021-10", "round": "战略增长投资（控股）", "amount": "$4.3 亿", "role": "领投", "post": "", "src": "https://ventures.mckesson.com/tag/saama/" } ], "sum_usd": 430000000 }, { "name": "Kleiner Perkins", "type": "VC / 基金", "companies": [ "Chai Discovery" ], "articles": [], "rounds": [ { "company": "Chai Discovery", "date": "2026-07", "round": "C 轮", "amount": "$400M", "role": "跟投", "post": "投后 $38 亿", "src": "https://www.zhiding.cn/energy/2026/0715/3193267.shtml" } ], "sum_usd": 400000000 }, { "name": "Sequoia", "type": "VC / 基金", "companies": [ "Chai Discovery" ], "articles": [], "rounds": [ { "company": "Chai Discovery", "date": "2026-07", "round": "C 轮", "amount": "$400M", "role": "跟投", "post": "投后 $38 亿", "src": "https://www.zhiding.cn/energy/2026/0715/3193267.shtml" } ], "sum_usd": 400000000 }, { "name": "CPP Investments", "type": "VC / 基金", "companies": [ "insitro" ], "articles": [], "rounds": [ { "company": "insitro", "date": "2021-03", "round": "C 轮", "amount": "$4 亿", "role": "领投", "post": "", "src": "https://www.fiercebiotech.com/biotech/astrazeneca-inks-15b-insitro-deal-ai-enabled-target-discovery" } ], "sum_usd": 400000000 }, { "name": "Bristol Myers Squibb", "type": "产业资本", "companies": [ "Pathos AI" ], "articles": [], "rounds": [ { "company": "Pathos AI", "date": "2026-10（日期待核）", "round": "新一轮", "amount": "$2.37 亿（未达 $3 亿目标）", "role": "领投", "post": "估值约 $30 亿", "src": "https://eu.36kr.com/en/p/4051860191958147" } ], "sum_usd": 237000000 }, { "name": "Nat Friedman", "type": "个人", "companies": [ "EvolutionaryScale" ], "articles": [], "rounds": [ { "company": "EvolutionaryScale", "date": "2024-06", "round": "种子轮", "amount": "$142M", "role": "领投", "post": "", "src": "https://pharmaphorum.com/news/evolutionaryscale-emerges-142m-ai-drug-discovery" } ], "sum_usd": 142000000 }, { "name": "Daniel Gross", "type": "个人", "companies": [ "EvolutionaryScale" ], "articles": [], "rounds": [ { "company": "EvolutionaryScale", "date": "2024-06", "round": "种子轮", "amount": "$142M", "role": "领投", "post": "", "src": "https://pharmaphorum.com/news/evolutionaryscale-emerges-142m-ai-drug-discovery" } ], "sum_usd": 142000000 }, { "name": "Amazon", "type": "产业资本", "companies": [ "EvolutionaryScale" ], "articles": [], "rounds": [ { "company": "EvolutionaryScale", "date": "2024-06", "round": "种子轮", "amount": "$142M", "role": "跟投", "post": "", "src": "https://pharmaphorum.com/news/evolutionaryscale-emerges-142m-ai-drug-discovery" } ], "sum_usd": 142000000 }, { "name": "Menlo Anthology Fund", "type": "VC / 基金", "companies": [ "Basecamp Research" ], "articles": [], "rounds": [ { "company": "Basecamp Research", "date": "2026-09", "round": "C 轮", "amount": "$140M", "role": "跟投", "post": "投后 $8 亿（媒体报道）", "src": "https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics" } ], "sum_usd": 140000000 }, { "name": "NATO Innovation Fund", "type": "VC / 基金", "companies": [ "Basecamp Research" ], "articles": [], "rounds": [ { "company": "Basecamp Research", "date": "2026-09", "round": "C 轮", "amount": "$140M", "role": "跟投", "post": "投后 $8 亿（媒体报道）", "src": "https://www.basecamp-research.com/news-research/basecamp-research-raises-140m-to-advance-ai-designed-therapeutics" } ], "sum_usd": 140000000 }, { "name": "Bedford Ridge Capital", "type": "VC / 基金", "companies": [ "Terray Therapeutics" ], "articles": [], "rounds": [ { "company": "Terray Therapeutics", "date": "2024-10", "round": "B 轮", "amount": "$1.2 亿", "role": "领投", "post": "", "src": "https://sogotradedev.websol.barchart.com/?module=topNews&storyID=29084499&selected=news&symbol=" } ], "sum_usd": 120000000 }, { "name": "Bezos Expeditions", "type": "VC / 基金", "companies": [ "Profluent" ], "articles": [], "rounds": [ { "company": "Profluent", "date": "2025-11", "round": "融资", "amount": "$106M", "role": "领投", "post": "", "src": "https://investor.wedbush.com/wedbush/article/bizwire-2025-11-19-profluent-raises-106m-to-scale-frontier-ai-models-for-programmable-biology" } ], "sum_usd": 106000000 }, { "name": "：光速中国", "type": "VC / 基金", "companies": [ "望石智慧 Stonewise" ], "articles": [], "rounds": [ { "company": "望石智慧 Stonewise", "date": "2025-04", "round": "B 轮与 B+ 轮", "amount": "合计 $1 亿", "role": "领投", "post": "", "src": "https://news.dayoo.com/finance/202603/25/171077_54940419.htm" } ], "sum_usd": 100000000 }, { "name": "大湾区共同家园发展基金", "type": "VC / 基金", "companies": [ "望石智慧 Stonewise" ], "articles": [], "rounds": [ { "company": "望石智慧 Stonewise", "date": "2025-04", "round": "B 轮与 B+ 轮", "amount": "合计 $1 亿", "role": "领投", "post": "", "src": "https://news.dayoo.com/finance/202603/25/171077_54940419.htm" } ], "sum_usd": 100000000 }, { "name": "：君联资本", "type": "VC / 基金", "companies": [ "望石智慧 Stonewise" ], "articles": [], "rounds": [ { "company": "望石智慧 Stonewise", "date": "2025-04", "round": "B 轮与 B+ 轮", "amount": "合计 $1 亿", "role": "领投", "post": "", "src": "https://news.dayoo.com/finance/202603/25/171077_54940419.htm" } ], "sum_usd": 100000000 }, { "name": "Adage", "type": "VC / 基金", "companies": [ "Absci" ], "articles": [], "rounds": [ { "company": "Absci", "date": "2026-06", "round": "承销公开发行", "amount": "$1 亿（含 Eli Lilly $4000 万战略投资）", "role": "领投", "post": "", "src": "https://investors.absci.com/news-and-events/news-releases" } ], "sum_usd": 100000000 }, { "name": "BVF", "type": "VC / 基金", "companies": [ "Absci" ], "articles": [], "rounds": [ { "company": "Absci", "date": "2026-06", "round": "承销公开发行", "amount": "$1 亿（含 Eli Lilly $4000 万战略投资）", "role": "领投", "post": "", "src": "https://investors.absci.com/news-and-events/news-releases" } ], "sum_usd": 100000000 }, { "name": "Columbia Threadneedle", "type": "VC / 基金", "companies": [ "Absci" ], "articles": [], "rounds": [ { "company": "Absci", "date": "2026-06", "round": "承销公开发行", "amount": "$1 亿（含 Eli Lilly $4000 万战略投资）", "role": "领投", "post": "", "src": "https://investors.absci.com/news-and-events/news-releases" } ], "sum_usd": 100000000 }, { "name": "Invus", "type": "VC / 基金", "companies": [ "Absci" ], "articles": [], "rounds": [ { "company": "Absci", "date": "2026-06", "round": "承销公开发行", "amount": "$1 亿（含 Eli Lilly $4000 万战略投资）", "role": "领投", "post": "", "src": "https://investors.absci.com/news-and-events/news-releases" } ], "sum_usd": 100000000 }, { "name": "Redmile", "type": "VC / 基金", "companies": [ "Absci" ], "articles": [], "rounds": [ { "company": "Absci", "date": "2026-06", "round": "承销公开发行", "amount": "$1 亿（含 Eli Lilly $4000 万战略投资）", "role": "领投", "post": "", "src": "https://investors.absci.com/news-and-events/news-releases" } ], "sum_usd": 100000000 }, { "name": "国寿资本", "type": "VC / 基金", "companies": [ "百奥几何 BioGeometry" ], "articles": [], "rounds": [ { "company": "百奥几何 BioGeometry", "date": "2026-10", "round": "A+ 轮", "amount": "A 轮系列累计超 $1 亿", "role": "领投", "post": "", "src": "https://36kr.com/p/4045277817411209" } ], "sum_usd": 100000000 }, { "name": "上海生物医药基金", "type": "VC / 基金", "companies": [ "百奥几何 BioGeometry" ], "articles": [], "rounds": [ { "company": "百奥几何 BioGeometry", "date": "2026-10", "round": "A+ 轮", "amount": "A 轮系列累计超 $1 亿", "role": "跟投", "post": "", "src": "https://36kr.com/p/4045277817411209" } ], "sum_usd": 100000000 }, { "name": "国开科创", "type": "VC / 基金", "companies": [ "百奥几何 BioGeometry" ], "articles": [], "rounds": [ { "company": "百奥几何 BioGeometry", "date": "2026-10", "round": "A+ 轮", "amount": "A 轮系列累计超 $1 亿", "role": "跟投", "post": "", "src": "https://36kr.com/p/4045277817411209" } ], "sum_usd": 100000000 }, { "name": "瑞力", "type": "VC / 基金", "companies": [ "百奥几何 BioGeometry" ], "articles": [], "rounds": [ { "company": "百奥几何 BioGeometry", "date": "2026-10", "round": "A+ 轮", "amount": "A 轮系列累计超 $1 亿", "role": "跟投", "post": "", "src": "https://36kr.com/p/4045277817411209" } ], "sum_usd": 100000000 }, { "name": "国方", "type": "VC / 基金", "companies": [ "百奥几何 BioGeometry" ], "articles": [], "rounds": [ { "company": "百奥几何 BioGeometry", "date": "2026-10", "round": "A+ 轮", "amount": "A 轮系列累计超 $1 亿", "role": "跟投", "post": "", "src": "https://36kr.com/p/4045277817411209" } ], "sum_usd": 100000000 }, { "name": "达晨", "type": "VC / 基金", "companies": [ "百奥几何 BioGeometry" ], "articles": [], "rounds": [ { "company": "百奥几何 BioGeometry", "date": "2026-10", "round": "A+ 轮", "amount": "A 轮系列累计超 $1 亿", "role": "跟投", "post": "", "src": "https://36kr.com/p/4045277817411209" } ], "sum_usd": 100000000 }, { "name": "蓝桥资本", "type": "VC / 基金", "companies": [ "分子之心 MoleculeMind" ], "articles": [], "rounds": [ { "company": "分子之心 MoleculeMind", "date": "2026-06", "round": "A 轮系列", "amount": "累计逾 $1 亿", "role": "领投", "post": "", "src": "https://stcn.com/article/detail/3967285.html" } ], "sum_usd": 100000000 }, { "name": "浦东创投", "type": "VC / 基金", "companies": [ "分子之心 MoleculeMind" ], "articles": [], "rounds": [ { "company": "分子之心 MoleculeMind", "date": "2026-06", "round": "A 轮系列", "amount": "累计逾 $1 亿", "role": "领投", "post": "", "src": "https://stcn.com/article/detail/3967285.html" } ], "sum_usd": 100000000 }, { "name": "中粮新兴产业基金", "type": "VC / 基金", "companies": [ "分子之心 MoleculeMind" ], "articles": [], "rounds": [ { "company": "分子之心 MoleculeMind", "date": "2026-06", "round": "A 轮系列", "amount": "累计逾 $1 亿", "role": "领投", "post": "", "src": "https://stcn.com/article/detail/3967285.html" } ], "sum_usd": 100000000 }, { "name": "东方富海", "type": "VC / 基金", "companies": [ "分子之心 MoleculeMind" ], "articles": [], "rounds": [ { "company": "分子之心 MoleculeMind", "date": "2026-06", "round": "A 轮系列", "amount": "累计逾 $1 亿", "role": "领投", "post": "", "src": "https://stcn.com/article/detail/3967285.html" } ], "sum_usd": 100000000 }, { "name": "复星创富等参", "type": "VC / 基金", "companies": [ "分子之心 MoleculeMind" ], "articles": [], "rounds": [ { "company": "分子之心 MoleculeMind", "date": "2026-06", "round": "A 轮系列", "amount": "累计逾 $1 亿", "role": "领投", "post": "", "src": "https://stcn.com/article/detail/3967285.html" } ], "sum_usd": 100000000 }, { "name": "BlackRock 旗下基金", "type": "VC / 基金", "companies": [ "Verge Genomics（现 Verge Labs）" ], "articles": [], "rounds": [ { "company": "Verge Genomics（现 Verge Labs）", "date": "2021-12", "round": "B 轮", "amount": "$98M（Form D 为 $85M）", "role": "领投", "post": "", "src": "https://healthcareventurecapitalfund.com/companies/verge-genomics/" } ], "sum_usd": 98000000 }, { "name": "NEA", "type": "VC / 基金", "companies": [ "Charm Therapeutics" ], "articles": [], "rounds": [ { "company": "Charm Therapeutics", "date": "2025-09", "round": "B 轮", "amount": "$8000 万", "role": "领投", "post": "", "src": "https://multiples.vc/private-comps/charm-therapeutics" } ], "sum_usd": 80000000 }, { "name": "SR One", "type": "VC / 基金", "companies": [ "Charm Therapeutics" ], "articles": [], "rounds": [ { "company": "Charm Therapeutics", "date": "2025-09", "round": "B 轮", "amount": "$8000 万", "role": "领投", "post": "", "src": "https://multiples.vc/private-comps/charm-therapeutics" } ], "sum_usd": 80000000 }, { "name": "OrbiMed", "type": "VC / 基金", "companies": [ "Charm Therapeutics" ], "articles": [], "rounds": [ { "company": "Charm Therapeutics", "date": "2025-09", "round": "B 轮", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://multiples.vc/private-comps/charm-therapeutics" } ], "sum_usd": 80000000 }, { "name": "Braidwell", "type": "VC / 基金", "companies": [ "Proxima（原 Vant AI）" ], "articles": [], "rounds": [ { "company": "Proxima（原 Vant AI）", "date": "2026-01", "round": "种子轮（改名 Proxima）", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://htworld.co.uk/news/ai/proxima-raises-us80-million-for-ai-drug-discovery-platform-lead26/" } ], "sum_usd": 80000000 }, { "name": "Roivant", "type": "VC / 基金", "companies": [ "Proxima（原 Vant AI）" ], "articles": [], "rounds": [ { "company": "Proxima（原 Vant AI）", "date": "2026-01", "round": "种子轮（改名 Proxima）", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://htworld.co.uk/news/ai/proxima-raises-us80-million-for-ai-drug-discovery-platform-lead26/" } ], "sum_usd": 80000000 }, { "name": "AIX", "type": "VC / 基金", "companies": [ "Proxima（原 Vant AI）" ], "articles": [], "rounds": [ { "company": "Proxima（原 Vant AI）", "date": "2026-01", "round": "种子轮（改名 Proxima）", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://htworld.co.uk/news/ai/proxima-raises-us80-million-for-ai-drug-discovery-platform-lead26/" } ], "sum_usd": 80000000 }, { "name": "Alexandria", "type": "VC / 基金", "companies": [ "Proxima（原 Vant AI）" ], "articles": [], "rounds": [ { "company": "Proxima（原 Vant AI）", "date": "2026-01", "round": "种子轮（改名 Proxima）", "amount": "$8000 万", "role": "跟投", "post": "", "src": "https://htworld.co.uk/news/ai/proxima-raises-us80-million-for-ai-drug-discovery-platform-lead26/" } ], "sum_usd": 80000000 }, { "name": "DFJ Growth 新进", "type": "VC / 基金", "companies": [ "Paradigm Health" ], "articles": [], "rounds": [ { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "跟投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" } ], "sum_usd": 78000000 }, { "name": "Mubadala", "type": "VC / 基金", "companies": [ "Paradigm Health" ], "articles": [], "rounds": [ { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "跟投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" } ], "sum_usd": 78000000 }, { "name": "美国癌症协会 BrightEdge 基金", "type": "VC / 基金", "companies": [ "Paradigm Health" ], "articles": [], "rounds": [ { "company": "Paradigm Health", "date": "2025-12", "round": "B 轮", "amount": "$78M", "role": "跟投", "post": "", "src": "https://www.thepharmaletter.com/pharma-news/78-million-series-b-for-tech-co-promising-rebuild-of-clinical-research-ecosystem" } ], "sum_usd": 78000000 }, { "name": "Premji Invest", "type": "VC / 基金", "companies": [ "BigHat Biosciences" ], "articles": [], "rounds": [ { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "领投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" } ], "sum_usd": 75000000 }, { "name": "LG Technology Ventures", "type": "VC / 基金", "companies": [ "BigHat Biosciences" ], "articles": [], "rounds": [ { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "跟投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" } ], "sum_usd": 75000000 }, { "name": "Sigmas 及 Lilly", "type": "VC / 基金", "companies": [ "BigHat Biosciences" ], "articles": [], "rounds": [ { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "跟投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" } ], "sum_usd": 75000000 }, { "name": "Amgen Ventures", "type": "VC / 基金", "companies": [ "BigHat Biosciences" ], "articles": [], "rounds": [ { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "跟投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" } ], "sum_usd": 75000000 }, { "name": "Merck GHI", "type": "产业资本", "companies": [ "BigHat Biosciences" ], "articles": [], "rounds": [ { "company": "BigHat Biosciences", "date": "2026-09", "round": "C 轮", "amount": "$7500 万", "role": "跟投", "post": "", "src": "https://www.bighatbio.com/news/bighat-biosciences-announces-75-million-series-c-financing" } ], "sum_usd": 75000000 }, { "name": "IVP", "type": "VC / 基金", "companies": [ "Cradle" ], "articles": [], "rounds": [ { "company": "Cradle", "date": "2024-11", "round": "B 轮", "amount": "$73M", "role": "领投", "post": "", "src": "https://www.synbiobeta.com/read/ai-powered-protein-engineering-heightened-by-cradle-bios-73m-series-b" } ], "sum_usd": 73000000 }, { "name": "Kindred Capital", "type": "VC / 基金", "companies": [ "Cradle" ], "articles": [], "rounds": [ { "company": "Cradle", "date": "2024-11", "round": "B 轮", "amount": "$73M", "role": "跟投", "post": "", "src": "https://www.synbiobeta.com/read/ai-powered-protein-engineering-heightened-by-cradle-bios-73m-series-b" } ], "sum_usd": 73000000 }, { "name": "Menlo Ventures", "type": "VC / 基金", "companies": [ "Vilya" ], "articles": [], "rounds": [ { "company": "Vilya", "date": "2024-06", "round": "A 轮扩展", "amount": "总额 $7100 万", "role": "跟投", "post": "", "src": "https://cen.acs.org/pharmaceuticals/drug-discovery/Vilya-designs-new-macrocyclic-peptides/102/i35" } ], "sum_usd": 71000000 }, { "name": "Spark Capital", "type": "VC / 基金", "companies": [ "Edison Scientific（FutureHouse）" ], "articles": [], "rounds": [ { "company": "Edison Scientific（FutureHouse）", "date": "2025-12", "round": "种子轮", "amount": "$70M", "role": "领投", "post": "投后 $2.5 亿", "src": "https://www.bloomberg.com/news/articles/2025-12-18/ai-startup-edison-raises-70-million-to-speed-up-scientific-research" } ], "sum_usd": 70000000 }, { "name": "Triatomic Capital", "type": "VC / 基金", "companies": [ "Edison Scientific（FutureHouse）" ], "articles": [], "rounds": [ { "company": "Edison Scientific（FutureHouse）", "date": "2025-12", "round": "种子轮", "amount": "$70M", "role": "领投", "post": "投后 $2.5 亿", "src": "https://www.bloomberg.com/news/articles/2025-12-18/ai-startup-edison-raises-70-million-to-speed-up-scientific-research" } ], "sum_usd": 70000000 }, { "name": "外加一家未具名美国生物科技投资者", "type": "VC / 基金", "companies": [ "Edison Scientific（FutureHouse）" ], "articles": [], "rounds": [ { "company": "Edison Scientific（FutureHouse）", "date": "2025-12", "round": "种子轮", "amount": "$70M", "role": "跟投", "post": "投后 $2.5 亿", "src": "https://www.bloomberg.com/news/articles/2025-12-18/ai-startup-edison-raises-70-million-to-speed-up-scientific-research" } ], "sum_usd": 70000000 }, { "name": "Jeff Dean 等天使", "type": "VC / 基金", "companies": [ "Edison Scientific（FutureHouse）" ], "articles": [], "rounds": [ { "company": "Edison Scientific（FutureHouse）", "date": "2025-12", "round": "种子轮", "amount": "$70M", "role": "跟投", "post": "投后 $2.5 亿", "src": "https://www.bloomberg.com/news/articles/2025-12-18/ai-startup-edison-raises-70-million-to-speed-up-scientific-research" } ], "sum_usd": 70000000 }, { "name": "Human Capital", "type": "VC / 基金", "companies": [ "Medra" ], "articles": [], "rounds": [ { "company": "Medra", "date": "2025-12", "round": "A 轮", "amount": "$52M", "role": "领投", "post": "", "src": "https://www.medra.ai/series-a" } ], "sum_usd": 52000000 }, { "name": "方未查全", "type": "VC / 基金", "companies": [ "Manas AI" ], "articles": [], "rounds": [ { "company": "Manas AI", "date": "2025", "round": "两轮种子", "amount": "超过 $5000 万", "role": "跟投", "post": "", "src": "https://thenextweb.com/news/reid-hoffman-leaves-microsoft-board-manas" } ], "sum_usd": 50000000 }, { "name": "Warburg Pincus", "type": "VC / 基金", "companies": [ "Helix" ], "articles": [], "rounds": [ { "company": "Helix", "date": "2021-06", "round": "C 轮", "amount": "$50M", "role": "领投", "post": "", "src": "https://profiles.crustdata.com/company/helix-631692" } ], "sum_usd": 50000000 }, { "name": "R42 Group", "type": "VC / 基金", "companies": [ "Healx" ], "articles": [], "rounds": [ { "company": "Healx", "date": "2024-08", "round": "C 轮", "amount": "$4700 万", "role": "领投", "post": "", "src": "https://healx.ai/healx-announces-47-million-series-c-financing-and-fda-clearance-of-phase-2-ind-for-neurofibromatosis-type-1-trial/" } ], "sum_usd": 47000000 }, { "name": "Atomico", "type": "VC / 基金", "companies": [ "Healx" ], "articles": [], "rounds": [ { "company": "Healx", "date": "2024-08", "round": "C 轮", "amount": "$4700 万", "role": "领投", "post": "", "src": "https://healx.ai/healx-announces-47-million-series-c-financing-and-fda-clearance-of-phase-2-ind-for-neurofibromatosis-type-1-trial/" } ], "sum_usd": 47000000 }, { "name": "Qumra Capital", "type": "VC / 基金", "companies": [ "QuantHealth" ], "articles": [], "rounds": [ { "company": "QuantHealth", "date": "2026-08", "round": "B 轮", "amount": "$45M", "role": "领投", "post": "", "src": "https://hitconsultant.net/2026/08/04/beyond-real-world-trial-iteration-quanthealth-secures-45m-for-ai-clinical-simulation/" } ], "sum_usd": 45000000 }, { "name": "Pitango HealthTech", "type": "VC / 基金", "companies": [ "QuantHealth" ], "articles": [], "rounds": [ { "company": "QuantHealth", "date": "2026-08", "round": "B 轮", "amount": "$45M", "role": "跟投", "post": "", "src": "https://hitconsultant.net/2026/08/04/beyond-real-world-trial-iteration-quanthealth-secures-45m-for-ai-clinical-simulation/" } ], "sum_usd": 45000000 }, { "name": "Bertelsmann Healthcare Investments", "type": "VC / 基金", "companies": [ "QuantHealth" ], "articles": [], "rounds": [ { "company": "QuantHealth", "date": "2026-08", "round": "B 轮", "amount": "$45M", "role": "跟投", "post": "", "src": "https://hitconsultant.net/2026/08/04/beyond-real-world-trial-iteration-quanthealth-secures-45m-for-ai-clinical-simulation/" } ], "sum_usd": 45000000 }, { "name": "Danaher Ventures 战略投资", "type": "VC / 基金", "companies": [ "Automata" ], "articles": [], "rounds": [ { "company": "Automata", "date": "2026-01", "round": "C 轮", "amount": "$45M", "role": "跟投", "post": "", "src": "https://www.rdworldonline.com/automata-raises-45m-to-scale-lab-automation-platform-adds-danaher-as-strategic-investor/" } ], "sum_usd": 45000000 }, { "name": "Octopus", "type": "VC / 基金", "companies": [ "Automata" ], "articles": [], "rounds": [ { "company": "Automata", "date": "2026-01", "round": "C 轮", "amount": "$45M", "role": "跟投", "post": "", "src": "https://www.rdworldonline.com/automata-raises-45m-to-scale-lab-automation-platform-adds-danaher-as-strategic-investor/" } ], "sum_usd": 45000000 }, { "name": "Entrepreneurs First", "type": "VC / 基金", "companies": [ "Automata" ], "articles": [], "rounds": [ { "company": "Automata", "date": "2026-01", "round": "C 轮", "amount": "$45M", "role": "跟投", "post": "", "src": "https://www.rdworldonline.com/automata-raises-45m-to-scale-lab-automation-platform-adds-danaher-as-strategic-investor/" } ], "sum_usd": 45000000 }, { "name": "Tru Arrow", "type": "VC / 基金", "companies": [ "Automata" ], "articles": [], "rounds": [ { "company": "Automata", "date": "2026-01", "round": "C 轮", "amount": "$45M", "role": "跟投", "post": "", "src": "https://www.rdworldonline.com/automata-raises-45m-to-scale-lab-automation-platform-adds-danaher-as-strategic-investor/" } ], "sum_usd": 45000000 }, { "name": "a16z Bio + Health", "type": "VC / 基金", "companies": [ "Arda Therapeutics" ], "articles": [], "rounds": [ { "company": "Arda Therapeutics", "date": "2024-10", "round": "A 轮", "amount": "$4300 万", "role": "领投", "post": "", "src": "https://www.ardatx.com/news/arda-therapeutics-secures-43m-series-a-financing-to-advance-targeted-cell-depletion-therapies" } ], "sum_usd": 43000000 }, { "name": "Two Sigma", "type": "VC / 基金", "companies": [ "Arda Therapeutics" ], "articles": [], "rounds": [ { "company": "Arda Therapeutics", "date": "2024-10", "round": "A 轮", "amount": "$4300 万", "role": "跟投", "post": "", "src": "https://www.ardatx.com/news/arda-therapeutics-secures-43m-series-a-financing-to-advance-targeted-cell-depletion-therapies" } ], "sum_usd": 43000000 }, { "name": "Mission BioCapital", "type": "VC / 基金", "companies": [ "AI Proteins" ], "articles": [], "rounds": [ { "company": "AI Proteins", "date": "2025-11", "round": "A 轮", "amount": "$4150 万", "role": "领投", "post": "", "src": "https://investor.wedbush.com/wedbush/article/bizwire-2025-11-19-ai-proteins-raises-415m-series-a-financing-to-advance-de-novo-miniproteins-as-a-new-therapeutic-modality" } ], "sum_usd": 41500000 }, { "name": "Santé Ventures", "type": "VC / 基金", "companies": [ "AI Proteins" ], "articles": [], "rounds": [ { "company": "AI Proteins", "date": "2025-11", "round": "A 轮", "amount": "$4150 万", "role": "领投", "post": "", "src": "https://investor.wedbush.com/wedbush/article/bizwire-2025-11-19-ai-proteins-raises-415m-series-a-financing-to-advance-de-novo-miniproteins-as-a-new-therapeutic-modality" } ], "sum_usd": 41500000 }, { "name": "Lightchain", "type": "VC / 基金", "companies": [ "AI Proteins" ], "articles": [], "rounds": [ { "company": "AI Proteins", "date": "2025-11", "round": "A 轮", "amount": "$4150 万", "role": "跟投", "post": "", "src": "https://investor.wedbush.com/wedbush/article/bizwire-2025-11-19-ai-proteins-raises-415m-series-a-financing-to-advance-de-novo-miniproteins-as-a-new-therapeutic-modality" } ], "sum_usd": 41500000 }, { "name": "Cobro", "type": "VC / 基金", "companies": [ "AI Proteins" ], "articles": [], "rounds": [ { "company": "AI Proteins", "date": "2025-11", "round": "A 轮", "amount": "$4150 万", "role": "跟投", "post": "", "src": "https://investor.wedbush.com/wedbush/article/bizwire-2025-11-19-ai-proteins-raises-415m-series-a-financing-to-advance-de-novo-miniproteins-as-a-new-therapeutic-modality" } ], "sum_usd": 41500000 }, { "name": "Polaris Partners", "type": "VC / 基金", "companies": [ "Noetik" ], "articles": [], "rounds": [ { "company": "Noetik", "date": "2024-08", "round": "A 轮", "amount": "$40M", "role": "领投", "post": "", "src": "https://www.businesswire.com/news/home/20240829428359/en/Noetik-Secures-$40-Million-Series-A-Financing-to-Advance-Precision-Cancer-Therapies" } ], "sum_usd": 40000000 }, { "name": "Wittington", "type": "VC / 基金", "companies": [ "Noetik" ], "articles": [], "rounds": [ { "company": "Noetik", "date": "2024-08", "round": "A 轮", "amount": "$40M", "role": "跟投", "post": "", "src": "https://www.businesswire.com/news/home/20240829428359/en/Noetik-Secures-$40-Million-Series-A-Financing-to-Advance-Precision-Cancer-Therapies" } ], "sum_usd": 40000000 }, { "name": "Breakout", "type": "VC / 基金", "companies": [ "Noetik" ], "articles": [], "rounds": [ { "company": "Noetik", "date": "2024-08", "round": "A 轮", "amount": "$40M", "role": "跟投", "post": "", "src": "https://www.businesswire.com/news/home/20240829428359/en/Noetik-Secures-$40-Million-Series-A-Financing-to-Advance-Precision-Cancer-Therapies" } ], "sum_usd": 40000000 }, { "name": "Merck Global Health Innovation Fund", "type": "产业资本", "companies": [ "Faro Health" ], "articles": [], "rounds": [ { "company": "Faro Health", "date": "2026-08", "round": "B 轮", "amount": "$37.3M", "role": "领投", "post": "", "src": "https://catalyze.gunder.com/en/news-insights/client-news/faro-ai-announces-dollar373-million-series-b" } ], "sum_usd": 37300000 }, { "name": "Northpond", "type": "VC / 基金", "companies": [ "Faro Health" ], "articles": [], "rounds": [ { "company": "Faro Health", "date": "2026-08", "round": "B 轮", "amount": "$37.3M", "role": "跟投", "post": "", "src": "https://catalyze.gunder.com/en/news-insights/client-news/faro-ai-announces-dollar373-million-series-b" } ], "sum_usd": 37300000 }, { "name": "Polaris", "type": "VC / 基金", "companies": [ "Faro Health" ], "articles": [], "rounds": [ { "company": "Faro Health", "date": "2026-08", "round": "B 轮", "amount": "$37.3M", "role": "跟投", "post": "", "src": "https://catalyze.gunder.com/en/news-insights/client-news/faro-ai-announces-dollar373-million-series-b" } ], "sum_usd": 37300000 }, { "name": "PTX", "type": "VC / 基金", "companies": [ "Faro Health" ], "articles": [], "rounds": [ { "company": "Faro Health", "date": "2026-08", "round": "B 轮", "amount": "$37.3M", "role": "跟投", "post": "", "src": "https://catalyze.gunder.com/en/news-insights/client-news/faro-ai-announces-dollar373-million-series-b" } ], "sum_usd": 37300000 }, { "name": "Compound", "type": "VC / 基金", "companies": [ "Achira" ], "articles": [], "rounds": [ { "company": "Achira", "date": "2025-02", "round": "种子/A 轮（媒体称法不一）", "amount": "$3300 万", "role": "跟投", "post": "", "src": "https://www.powergame.gr/start-ups-digital/812090/achira-33-ekat-dolaria-apo-tin-nvidia-sti-startup-me-to-elliniko-dna/" } ], "sum_usd": 33000000 }, { "name": "DFJ", "type": "VC / 基金", "companies": [ "Verge Genomics（现 Verge Labs）" ], "articles": [], "rounds": [ { "company": "Verge Genomics（现 Verge Labs）", "date": "2018-07", "round": "A 轮", "amount": "$32M", "role": "领投", "post": "", "src": "https://healthcarediscovery.ai/companies/verge-genomics/" } ], "sum_usd": 32000000 }, { "name": "Zetta Venture Partners", "type": "VC / 基金", "companies": [ "Boltz" ], "articles": [], "rounds": [ { "company": "Boltz", "date": "2026-01", "round": "种子轮", "amount": "$28M", "role": "领投", "post": "", "src": "https://www.communityjameel.org/news/mit-jameel-clinic-spinout-boltz-launches-new-platform-and-agents-announces-usd-28m-seed-round" } ], "sum_usd": 28000000 }, { "name": "Clement Delangue 等天使", "type": "VC / 基金", "companies": [ "Boltz" ], "articles": [], "rounds": [ { "company": "Boltz", "date": "2026-01", "round": "种子轮", "amount": "$28M", "role": "跟投", "post": "", "src": "https://www.communityjameel.org/news/mit-jameel-clinic-spinout-boltz-launches-new-platform-and-agents-announces-usd-28m-seed-round" } ], "sum_usd": 28000000 }, { "name": "a16z Bio+Health", "type": "VC / 基金", "companies": [ "Inductive Bio" ], "articles": [], "rounds": [ { "company": "Inductive Bio", "date": "2025-05", "round": "A 轮", "amount": "$2500 万", "role": "跟投", "post": "", "src": "https://www.finsmes.com/2025/05/inductive-bio-raises-25m-in-series-a-funding.html" } ], "sum_usd": 25000000 }, { "name": "Character", "type": "VC / 基金", "companies": [ "Inductive Bio" ], "articles": [], "rounds": [ { "company": "Inductive Bio", "date": "2025-05", "round": "A 轮", "amount": "$2500 万", "role": "跟投", "post": "", "src": "https://www.finsmes.com/2025/05/inductive-bio-raises-25m-in-series-a-funding.html" } ], "sum_usd": 25000000 }, { "name": "Amino Collective", "type": "VC / 基金", "companies": [ "Inductive Bio" ], "articles": [], "rounds": [ { "company": "Inductive Bio", "date": "2025-05", "round": "A 轮", "amount": "$2500 万", "role": "跟投", "post": "", "src": "https://www.finsmes.com/2025/05/inductive-bio-raises-25m-in-series-a-funding.html" } ], "sum_usd": 25000000 }, { "name": "Madrona", "type": "VC / 基金", "companies": [ "Archon Biosciences" ], "articles": [], "rounds": [ { "company": "Archon Biosciences", "date": "2024-10", "round": "种子轮", "amount": "$2000 万", "role": "领投", "post": "", "src": "https://parsers.vc/startup/archon.bio/" } ], "sum_usd": 20000000 }, { "name": "redalpine", "type": "VC / 基金", "companies": [ "Helical" ], "articles": [], "rounds": [ { "company": "Helical", "date": "2026-04", "round": "种子轮", "amount": "$10M", "role": "领投", "post": "", "src": "https://thenextweb.com/news/helical-10m-seed-bio-foundation-models-pharma-ai" } ], "sum_usd": 10000000 }, { "name": "Gradient", "type": "VC / 基金", "companies": [ "Helical" ], "articles": [], "rounds": [ { "company": "Helical", "date": "2026-04", "round": "种子轮", "amount": "$10M", "role": "跟投", "post": "", "src": "https://thenextweb.com/news/helical-10m-seed-bio-foundation-models-pharma-ai" } ], "sum_usd": 10000000 }, { "name": "BoxGroup", "type": "VC / 基金", "companies": [ "Helical" ], "articles": [], "rounds": [ { "company": "Helical", "date": "2026-04", "round": "种子轮", "amount": "$10M", "role": "跟投", "post": "", "src": "https://thenextweb.com/news/helical-10m-seed-bio-foundation-models-pharma-ai" } ], "sum_usd": 10000000 }, { "name": "Frst", "type": "VC / 基金", "companies": [ "Helical" ], "articles": [], "rounds": [ { "company": "Helical", "date": "2026-04", "round": "种子轮", "amount": "$10M", "role": "跟投", "post": "", "src": "https://thenextweb.com/news/helical-10m-seed-bio-foundation-models-pharma-ai" } ], "sum_usd": 10000000 }, { "name": "Wendel", "type": "VC / 基金", "companies": [ "Aqemia" ], "articles": [], "rounds": [ { "company": "Aqemia", "date": "2024", "round": "融资", "amount": "7000 万（币种未显示）", "role": "领投", "post": "", "src": "https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2026/03/Aqemia_FactSheet_Screen.pdf" } ], "sum_usd": 0 }, { "name": "Bpifrance", "type": "VC / 基金", "companies": [ "Aqemia" ], "articles": [], "rounds": [ { "company": "Aqemia", "date": "2024", "round": "融资", "amount": "7000 万（币种未显示）", "role": "领投", "post": "", "src": "https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2026/03/Aqemia_FactSheet_Screen.pdf" } ], "sum_usd": 0 }, { "name": "Eurazeo", "type": "VC / 基金", "companies": [ "Aqemia" ], "articles": [], "rounds": [ { "company": "Aqemia", "date": "2024", "round": "融资", "amount": "7000 万（币种未显示）", "role": "领投", "post": "", "src": "https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2026/03/Aqemia_FactSheet_Screen.pdf" } ], "sum_usd": 0 }, { "name": "Elaia 参", "type": "VC / 基金", "companies": [ "Aqemia" ], "articles": [], "rounds": [ { "company": "Aqemia", "date": "2024", "round": "融资", "amount": "7000 万（币种未显示）", "role": "领投", "post": "", "src": "https://event.businessfrance.fr/business-france-at-bio-convention/wp-content/uploads/sites/1378/2026/03/Aqemia_FactSheet_Screen.pdf" } ], "sum_usd": 0 }, { "name": "红点中国", "type": "VC / 基金", "companies": [ "星药科技 Galixir" ], "articles": [], "rounds": [ { "company": "星药科技 Galixir", "date": "2020-12", "round": "两轮（数千万美元）", "amount": "数千万美元", "role": "领投", "post": "", "src": "https://startup.aliyun.com/info/106121.html" } ], "sum_usd": 0 }, { "name": "五源资本", "type": "VC / 基金", "companies": [ "星药科技 Galixir" ], "articles": [], "rounds": [ { "company": "星药科技 Galixir", "date": "2020-12", "round": "两轮（数千万美元）", "amount": "数千万美元", "role": "领投", "post": "", "src": "https://startup.aliyun.com/info/106121.html" } ], "sum_usd": 0 }, { "name": "讯飞创投", "type": "VC / 基金", "companies": [ "费米子科技 Fermion" ], "articles": [], "rounds": [ { "company": "费米子科技 Fermion", "date": "2022-07", "round": "B 轮", "amount": "超亿元人民币", "role": "领投", "post": "", "src": "https://bydrug.pharmcube.com/news/summary/tag/AI%20Biotech" } ], "sum_usd": 0 }, { "name": "正轩资本", "type": "VC / 基金", "companies": [ "费米子科技 Fermion" ], "articles": [], "rounds": [ { "company": "费米子科技 Fermion", "date": "2022-07", "round": "B 轮", "amount": "超亿元人民币", "role": "领投", "post": "", "src": "https://bydrug.pharmcube.com/news/summary/tag/AI%20Biotech" } ], "sum_usd": 0 }, { "name": "熊猫资本", "type": "VC / 基金", "companies": [ "费米子科技 Fermion" ], "articles": [], "rounds": [ { "company": "费米子科技 Fermion", "date": "2022-07", "round": "B 轮", "amount": "超亿元人民币", "role": "跟投", "post": "", "src": "https://bydrug.pharmcube.com/news/summary/tag/AI%20Biotech" } ], "sum_usd": 0 }, { "name": "挑战者创投", "type": "VC / 基金", "companies": [ "费米子科技 Fermion" ], "articles": [], "rounds": [ { "company": "费米子科技 Fermion", "date": "2022-07", "round": "B 轮", "amount": "超亿元人民币", "role": "跟投", "post": "", "src": "https://bydrug.pharmcube.com/news/summary/tag/AI%20Biotech" } ], "sum_usd": 0 }, { "name": "Hargreave Hale AIM VCT 参", "type": "VC / 基金", "companies": [ "LabGenius" ], "articles": [], "rounds": [ { "company": "LabGenius", "date": "2026-02", "round": "B 轮延长（B 轮规模 £3500 万）", "amount": "延长金额未披露", "role": "领投", "post": "", "src": "https://www.hargreaveaimvcts.co.uk/news-and-events/vct-news/labgenius-therapeutics-investment/" } ], "sum_usd": 0 }, { "name": "M Ventures", "type": "产业资本", "companies": [ "Iktos" ], "articles": [], "rounds": [ { "company": "Iktos", "date": "2023-03", "round": "A 轮", "amount": "€1550 万", "role": "领投", "post": "", "src": "https://www.debiopharm.com/innovation-fund/portfolio/iktos/" } ], "sum_usd": 0 }, { "name": "Debiopharm", "type": "VC / 基金", "companies": [ "Iktos" ], "articles": [], "rounds": [ { "company": "Iktos", "date": "2023-03", "round": "A 轮", "amount": "€1550 万", "role": "领投", "post": "", "src": "https://www.debiopharm.com/innovation-fund/portfolio/iktos/" } ], "sum_usd": 0 }, { "name": "未明确领投方", "type": "VC / 基金", "companies": [ "深势科技 DP Technology" ], "articles": [], "rounds": [ { "company": "深势科技 DP Technology", "date": "2025-12", "round": "C 轮", "amount": "逾 8 亿元人民币", "role": "领投", "post": "投后逾 60 亿元人民币", "src": "https://www.bianews.com/news/details?id=228139" } ], "sum_usd": 0 }, { "name": "达晨财智", "type": "VC / 基金", "companies": [ "深势科技 DP Technology" ], "articles": [], "rounds": [ { "company": "深势科技 DP Technology", "date": "2025-12", "round": "C 轮", "amount": "逾 8 亿元人民币", "role": "领投", "post": "投后逾 60 亿元人民币", "src": "https://www.bianews.com/news/details?id=228139" } ], "sum_usd": 0 }, { "name": "联想创投", "type": "产业资本", "companies": [ "深势科技 DP Technology" ], "articles": [], "rounds": [ { "company": "深势科技 DP Technology", "date": "2025-12", "round": "C 轮", "amount": "逾 8 亿元人民币", "role": "领投", "post": "投后逾 60 亿元人民币", "src": "https://www.bianews.com/news/details?id=228139" } ], "sum_usd": 0 }, { "name": "元禾璞华", "type": "VC / 基金", "companies": [ "深势科技 DP Technology" ], "articles": [], "rounds": [ { "company": "深势科技 DP Technology", "date": "2025-12", "round": "C 轮", "amount": "逾 8 亿元人民币", "role": "领投", "post": "投后逾 60 亿元人民币", "src": "https://www.bianews.com/news/details?id=228139" } ], "sum_usd": 0 }, { "name": "京国瑞", "type": "VC / 基金", "companies": [ "深势科技 DP Technology" ], "articles": [], "rounds": [ { "company": "深势科技 DP Technology", "date": "2025-12", "round": "C 轮", "amount": "逾 8 亿元人民币", "role": "领投", "post": "投后逾 60 亿元人民币", "src": "https://www.bianews.com/news/details?id=228139" } ], "sum_usd": 0 }, { "name": "北京人工智能产业投资基金参", "type": "VC / 基金", "companies": [ "深势科技 DP Technology" ], "articles": [], "rounds": [ { "company": "深势科技 DP Technology", "date": "2025-12", "round": "C 轮", "amount": "逾 8 亿元人民币", "role": "领投", "post": "投后逾 60 亿元人民币", "src": "https://www.bianews.com/news/details?id=228139" } ], "sum_usd": 0 }, { "name": "药明康德（WuXi AppTec）；Reportify 整理", "type": "VC / 基金", "companies": [], "articles": [ { "title": "药明康德：订单及增长前景强劲，上调目标价；AI 药物研发或成为新收入来源（电话会纪要）", "date": "2026-10-28", "url": "https://www.reportify.cn/transcripts/1312777265616130048", "kind": "财报 / 投资者材料" } ], "rounds": [], "sum_usd": 0 }, { "name": "虎嗅（作者「小饭桌」）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "字节百度谷歌英伟达，挤进同一个赛道（AI 制药融资分析）", "date": "2026-10-19", "url": "https://www.huxiu.com/article/4898538.html", "kind": "媒体分析" } ], "rounds": [], "sum_usd": 0 }, { "name": "Air Street Capital", "type": "VC / 基金", "companies": [], "articles": [ { "title": "State of AI Report 2026（生物与药物发现部分）", "date": "2026-10", "url": "https://www.stateof.ai/", "kind": "年度预测" } ], "rounds": [], "sum_usd": 0 }, { "name": "英矽智能（Insilico Medicine，3696.HK）；蓝鲸新闻转述", "type": "VC / 基金", "companies": [], "articles": [ { "title": "英矽智能 2026 年半年报：扭亏为盈，核心候选药物进入 III 期临床（蓝鲸新闻）", "date": "2026-08-26", "url": "https://m.sohu.com/a/1068299004_250147/", "kind": "财报 / 投资者材料" } ], "rounds": [], "sum_usd": 0 }, { "name": "ZAKA VC", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Nobody at a frontier lab is working on your disease", "date": "2026-08-23", "url": "https://zaka.vc/nobody-at-a-frontier-lab-is-working-on-your-disease/", "kind": "赛道论点" }, { "title": "In AI drug discovery, the model was never the moat", "date": "2026-07-27", "url": "https://zaka.vc/in-ai-drug-discovery-the-model-was-never-the-moat/", "kind": "赛道论点" } ], "rounds": [], "sum_usd": 0 }, { "name": "晶泰控股（XtalPi，2228.HK）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "晶泰控股发布 2026 年中期业绩报告", "date": "2026-08-19", "url": "https://cn.investing.com/news/stock-market-news/article-3525925", "kind": "财报 / 投资者材料" } ], "rounds": [], "sum_usd": 0 }, { "name": "Absci", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results", "date": "2026-08-11", "url": "https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm", "kind": "财报 / 投资者材料" } ], "rounds": [], "sum_usd": 0 }, { "name": "Schrödinger", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Schrödinger Reports Second Quarter 2026 Financial Results", "date": "2026-08-05", "url": "https://ir.schrodinger.com/press-releases/news-details/2026/Schrdinger-Reports-Second-Quarter-2026-Financial-Results/default.aspx", "kind": "财报 / 投资者材料" }, { "title": "Schrödinger Reports Third Quarter 2025 Financial Results", "date": "2025-11-05", "url": "https://www.nasdaq.com/press-release/schrodinger-reports-third-quarter-2025-financial-results-2025-11-05", "kind": "财报 / 投资者材料" } ], "rounds": [], "sum_usd": 0 }, { "name": "Recursion", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program", "date": "2026-08-05", "url": "https://investor.wedbush.com/wedbush/article/gnwcq-2026-8-5-recursion-reports-second-quarter-financial-results-genentech-options-first-neuroscience-target-into-early-discovery-program", "kind": "财报 / 投资者材料" } ], "rounds": [], "sum_usd": 0 }, { "name": "ProMarket（芝加哥大学 Stigler 中心）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Pharma's AI Boom Has Bet on the Wrong Bottleneck", "date": "2026-07-02", "url": "https://www.promarket.org/2026/07/02/pharmas-ai-boom-has-bet-on-the-wrong-bottleneck/", "kind": "媒体分析" } ], "rounds": [], "sum_usd": 0 }, { "name": "a16z（Andreessen Horowitz）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Uneven Frontiers: How AI will transform biopharma — and why the sequence of change matters", "date": "2026-06-17", "url": "https://www.a16z.news/p/uneven-frontiers", "kind": "赛道论点" }, { "title": "Science at the speed of inference: A manifesto for biotech and open science, from Boltz", "date": "2026-01-08", "url": "https://www.a16z.news/p/science-at-the-speed-of-inference", "kind": "投资备忘" }, { "title": "Faster Science, Better Drugs", "date": "2025-09-16", "url": "https://www.a16z.news/p/faster-science-better-drugs", "kind": "媒体分析" } ], "rounds": [], "sum_usd": 0 }, { "name": "高瓴投资", "type": "VC / 基金", "companies": [], "articles": [ { "title": "高瓴联席首席投资官易诺青：AI 现在模型技术的发展，超出几乎所有人想象", "date": "2026-06-11", "url": "https://www.sohu.com/a/1035375165_122260497", "kind": "媒体分析" } ], "rounds": [], "sum_usd": 0 }, { "name": "MMC Ventures", "type": "VC / 基金", "companies": [], "articles": [ { "title": "AI x TechBio: Featuring the future of drug discovery（Part II）", "date": "2026-06-08", "url": "https://mmc.vc/research/ai-x-techbio-featuring-the-future-of-drug-discovery/", "kind": "市场地图" } ], "rounds": [], "sum_usd": 0 }, { "name": "William Blair（投行研究）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "How AI is Rewriting the Economics of Drug Development", "date": "2026-05-21", "url": "https://www.williamblair.com/Insights/How-AI-is-Rewriting-the-Economics-of-Drug-Development", "kind": "行业报告" } ], "rounds": [], "sum_usd": 0 }, { "name": "Deloitte", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Navigating the GLP-1 boom: Measuring the return from pharmaceutical innovation（第 16 版）", "date": "2026-05-04", "url": "https://www.deloitte.com/us/en/industries/life-sciences-health-care/perspectives/navigating-the-glp-boom.html", "kind": "行业报告" } ], "rounds": [], "sum_usd": 0 }, { "name": "The Century of Biology（Elliot Hershberg）；Amplify Partners 投资人", "type": "VC / 基金", "companies": [], "articles": [ { "title": "AI Versus Eroom's Law", "date": "2026-04-12", "url": "https://centuryofbio.com/p/eroom", "kind": "赛道论点" } ], "rounds": [], "sum_usd": 0 }, { "name": "XAnge", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Bio-Foundation Models: A Shift in AI for Biology", "date": "2026-04-09", "url": "https://www.xange.vc/knowledge-hub/bio-foundation-models-market-map", "kind": "市场地图" } ], "rounds": [], "sum_usd": 0 }, { "name": "William Blair（经 Carterra 转载）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "From Code to Clinic: How AI Is (and Isn't) Rewriting the Life of a Drug", "date": "2026-03-30", "url": "https://carterra-bio.com/resources/from-code-to-clinic-how-ai-is-and-isnt-rewriting-the-life-of-a-drug/", "kind": "行业报告" } ], "rounds": [], "sum_usd": 0 }, { "name": "Bessemer", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Roadmap: Reinventing life sciences with AI", "date": "2026-03-12", "url": "https://www.bvp.com/atlas/roadmap-reinventing-life-sciences-with-ai", "kind": "行业报告" } ], "rounds": [], "sum_usd": 0 }, { "name": "Bioptimus", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Why Biopharma Needs Its Own AI: Bio FMs vs LLMs", "date": "2025-12-17", "url": "https://www.bioptimus.com/news/biopharma-needs-own-ai-bio-fms-vs-llms", "kind": "媒体分析" } ], "rounds": [], "sum_usd": 0 }, { "name": "Speedinvest（与 Dealroom.co 合作）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "TechBio x AI Drug Discovery: From Concept to Reality", "date": "2025-12-04", "url": "https://www.speedinvest.com/knowledge/techbio-x-drug-discovery-from-concept-to-reality", "kind": "年度预测" } ], "rounds": [], "sum_usd": 0 }, { "name": "In Vivo Partners", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Pure AI Plays in Biotech: An Investor's Framework to Identify Value", "date": "2025-10", "url": "https://invivo.partners/wp-content/uploads/2025/10/pure_ai_plays_bio.pdf", "kind": "赛道论点" } ], "rounds": [], "sum_usd": 0 }, { "name": "CB Insights", "type": "VC / 基金", "companies": [], "articles": [ { "title": "The AI in drug R&D market map", "date": "2025-05-23", "url": "https://www.cbinsights.com/research/ai-drug-research-development-market-map/", "kind": "市场地图" } ], "rounds": [], "sum_usd": 0 }, { "name": "启明创投", "type": "VC / 基金", "companies": [], "articles": [ { "title": "启明观点 | 启明创投陈侃：AI 对生物医药行业的变革已经显现", "date": "2025-04-22", "url": "https://www.qimingvc.com/en/node/7261", "kind": "赛道论点" } ], "rounds": [], "sum_usd": 0 }, { "name": "Deloitte UK", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Be brave, be bold: Measuring the return from pharmaceutical innovation（第 15 版）", "date": "2025-04-01", "url": "https://www.deloitte.com/uk/en/blogs/thoughts-from-the-centre/be-brave-be-bold-measuring-the-return-from-pharmaceutical-innovation.html", "kind": "行业报告" } ], "rounds": [], "sum_usd": 0 }, { "name": "Loon（市场准入与 HEOR 公司）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "AI Drug Discovery's $60 Billion Reality Check: Hype, Failures, and the Market Access Blindspot", "date": "2024-12-31", "url": "https://loonbio.com/reflections/ai-drug-discoverys-60-billion-reality-check-hype-failures-and-the-market-access-blindspot", "kind": "媒体分析" } ], "rounds": [], "sum_usd": 0 }, { "name": "Lux Capital（Riskgaming 博客）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "The soon-to-be-solved protein problem that will accelerate drug discovery", "date": "2024-05-16", "url": "https://blog.riskgaming.com/p/the-soon-to-be-solved-protein-problem-that-will-accelerate-drug-discovery", "kind": "媒体分析" } ], "rounds": [], "sum_usd": 0 }, { "name": "a16z（Andreessen Horowitz）Bio + Health", "type": "VC / 基金", "companies": [], "articles": [ { "title": "AI at the Intersection: The a16z Investment Thesis on AI in Bio + Health", "date": "2023-06-21", "url": "https://a16z.com/ai-at-the-intersection-the-a16z-investment-thesis-on-ai-in-bio-health/", "kind": "赛道论点" }, { "title": "Doing More with Moore: Biotech's Tech Moment", "date": "2023-02-14", "url": "https://a16z.com/doing-more-with-moore-biotechs-tech-moment/", "kind": "赛道论点" } ], "rounds": [], "sum_usd": 0 }, { "name": "Nature 新闻特写（作者为 McKinsey & Company 员工）", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Understanding the company landscape in AI-driven biopharma R&D", "date": "2023-05-16", "url": "https://www.nature.com/articles/d43747-023-00020-4", "kind": "市场地图" } ], "rounds": [], "sum_usd": 0 }, { "name": "ARTIS Ventures", "type": "VC / 基金", "companies": [], "articles": [ { "title": "Where does AI fit in the therapeutics discovery equation?", "date": "2023", "url": "https://www.av.co/news/where-does-ai-fit-in-the-therapeutics-discovery-equation", "kind": "赛道论点" } ], "rounds": [], "sum_usd": 0 } ] }